The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

References

• Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol. 2015;6(1):187–214. doi:10.1002/cphy.c140055
   PubMed Web of Science ®Google Scholar
• Gibb AA, Hill BG. Metabolic coordination of physiological and pathological cardiac remodeling. Circ Res. 2018;123(1):107–128. doi:10.1161/CIRCRESAHA.118.312017
   PubMed Web of Science ®Google Scholar
• Tham YK, Bernardo BC, Ooi JYY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401–1438. doi:10.1007/s00204-015-1477-x
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15(7):387–407. doi:10.1038/s41569-018-0007-y
   PubMed Web of Science ®Google Scholar
• Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245–262. doi:10.1016/j.yjmcc.2016.06.001
   PubMed Web of Science ®Google Scholar
• Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41. doi:10.1038/nrcardio.2010.165
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012;180(5):2018–2027. doi:10.1016/j.ajpath.2012.01.028
   PubMed Web of Science ®Google Scholar
• Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018;128(7):2657–2669. doi:10.1172/JCI97943
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349–361. doi:10.1038/nri2294
   PubMed Web of Science ®Google Scholar
• Schmitz Nunes V, Rogerio AP, Abrahao O. Insights into the activation mechanism of the ALX/FPR2 receptor. J Phys Chem Lett. 2020;11(21):8952–8957. doi:10.1021/acs.jpclett.0c02052
   PubMed Web of Science ®Google Scholar
• Kain V, Ingle KA, Colas RA, et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol. 2015;84:24–35. doi:10.1016/j.yjmcc.2015.04.003
   PubMed Web of Science ®Google Scholar
• Wu B, Mottola G, Chatterjee A, et al. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J Vasc Surg. 2017;65(1):207–217 e3. doi:10.1016/j.jvs.2016.01.030
   PubMedGoogle Scholar
• Wang M, Liu M, Zhang J, et al. Resolvin D1 protects against sepsis-induced cardiac injury in mice. Biofactors. 2020;46(5):766–776. doi:10.1002/biof.1668
   PubMed Web of Science ®Google Scholar
• Olivares-Silva F, De Gregorio N, Espitia-Corredor J, et al. Resolvin-D1 attenuation of angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension. Biochim Biophys Acta Mol Basis Dis. 2021;1867(12):166241. doi:10.1016/j.bbadis.2021.166241
   PubMed Web of Science ®Google Scholar
• Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410
   PubMed Web of Science ®Google Scholar
• Hellmann J, Tang Y, Kosuri M, et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 2011;25(7):2399–2407. doi:10.1096/fj.10-178657
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang J, Yin Z, et al. Microglia-mediated neuroimmune response regulates cardiac remodeling after myocardial infarction. J Am Heart Assoc. 2023;12(12):e029053. doi:10.1161/jaha.122.029053
   PubMed Web of Science ®Google Scholar
• Suetomi T, Willeford A, Brand CS, et al. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca 2+ /calmodulin-dependent protein kinase II δ signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation. 2018;138(22):2530–2544. doi:10.1161/CIRCULATIONAHA.118.034621
   PubMed Web of Science ®Google Scholar
• Zheng L, Han P, Liu J, et al. Role of copper in regression of cardiac hypertrophy. Pharmacol Ther. 2015;148:66–84. doi:10.1016/j.pharmthera.2014.11.014
   PubMed Web of Science ®Google Scholar
• MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res. 2000;46(2):257–263. doi:10.1016/s0008-6363(00)00030-4
   PubMed Web of Science ®Google Scholar
• Ma ZG, Yuan Y-P, Wu H-M, et al. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14(12):1645–1657. doi:10.7150/ijbs.28103
   PubMed Web of Science ®Google Scholar
• Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81(4):627–635. doi:10.1161/01.res.81.4.627
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438. doi:10.1371/journal.pone.0033438
   PubMed Web of Science ®Google Scholar
• Melendez GC, McLarty JL, Levick SP, et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56(2):225–231. doi:10.1161/HYPERTENSIONAHA.109.148635
   PubMed Web of Science ®Google Scholar
• Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115(11):1398–1407. doi:10.1161/CIRCULATIONAHA.106.643585
   PubMed Web of Science ®Google Scholar
• Zhao L, Cheng G, Jin R, et al. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ Res. 2016;118(12):1918–1929. doi:10.1161/circresaha.116.308688
   PubMed Web of Science ®Google Scholar
• Lai NC, Gao MH, Tang E, et al. Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice. Lab Invest. 2012;92(11):1518–1526. doi:10.1038/labinvest.2012.97
   PubMed Web of Science ®Google Scholar
• Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131(11):1019–1030. doi:10.1161/CIRCULATIONAHA.114.008788
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu Y, Wang M, et al. TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice. EBioMedicine. 2018;36:54–62. doi:10.1016/j.ebiom.2018.08.022
   PubMed Web of Science ®Google Scholar
• Anderson P, Delgado M. Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders. J Cell Mol Med. 2008;12(5B):1830–1847. doi:10.1111/j.1582-4934.2008.00387.x
   PubMed Web of Science ®Google Scholar
• Fredman G, Spite M. Specialized pro-resolving mediators in cardiovascular diseases. Mol Aspects Med. 2017;58:65–71. doi:10.1016/j.mam.2017.02.003
   PubMed Web of Science ®Google Scholar
• Levy BD. Resolvin D1 and resolvin E1 promote the resolution of allergic airway inflammation via shared and distinct molecular counter-regulatory pathways. Front Immunol. 2012;3:390. doi:10.3389/fimmu.2012.00390
   PubMed Web of Science ®Google Scholar
• Carrillo I, Rabelo RAN, Barbosa C, et al. Aspirin-triggered resolvin D1 reduces parasitic cardiac load by decreasing inflammation in a murine model of early chronic Chagas disease. PLoS Negl Trop Dis. 2021;15(11):e0009978. doi:10.1371/journal.pntd.0009978
   PubMed Web of Science ®Google Scholar
• Hiram R, Xiong F, Naud P, et al. The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. Cardiovasc Res. 2021;117(7):1776–1789. doi:10.1093/cvr/cvaa186
   PubMed Web of Science ®Google Scholar
• Salas-Hernández A, Ruz-Cortés F, Bruggendieck F, et al. Resolvin D1 reduces expression and secretion of cytokines and monocyte adhesion triggered by angiotensin II, in rat cardiac fibroblasts. Biomed Pharmacother. 2021;141:111947. doi:10.1016/j.biopha.2021.111947
   PubMed Web of Science ®Google Scholar
• Kain V, Halade GV. Immune responsive resolvin D1 programs peritoneal macrophages and cardiac fibroblast phenotypes in diversified metabolic microenvironment. J Cell Physiol. 2019;234(4):3910–3920. doi:10.1002/jcp.27165
   PubMed Web of Science ®Google Scholar
• Yang D, Liu H-Q, Liu F-Y, et al. Critical roles of macrophages in pressure overload-induced cardiac remodeling. J Mol Med. 2021;99(1):33–46. doi:10.1007/s00109-020-02002-w
   PubMed Web of Science ®Google Scholar
• Gao R, Shi H, Chang S, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 2019;74:105575. doi:10.1016/j.intimp.2019.04.022
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–1361. doi:10.1038/nature08938
   PubMed Web of Science ®Google Scholar
• Toldo S, Marchetti C, Mauro AG, et al. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. Int J Cardiol. 2016;209:215–220. doi:10.1016/j.ijcard.2016.02.043
   PubMed Web of Science ®Google Scholar
• Li R, Lu K, Wang Y, et al. Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression. Biochem Biophys Res Commun. 2017;485(1):69–75. doi:10.1016/j.bbrc.2017.02.021
   PubMed Web of Science ®Google Scholar
• Yue R, Zheng Z, Luo Y, et al. NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin. Cell Death Discov. 2021;7(1):50. doi:10.1038/s41420-021-00434-y
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhang J, Xu Y, et al. Selective inhibition of NLRP3 inflammasome reverses pressure overload-induced pathological cardiac remodeling by attenuating hypertrophy, fibrosis, and inflammation. Int Immunopharmacol. 2021;99:108046. doi:10.1016/j.intimp.2021.108046
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210–215. doi:10.1038/nri2725
   PubMed Web of Science ®Google Scholar
• Posso SV, Quesnot N, Moraes JA, et al. AT-RVD1 repairs mouse lung after cigarette smoke-induced emphysema via downregulation of oxidative stress by NRF2/KEAP1 pathway. Int Immunopharmacol. 2018;56:330–338. doi:10.1016/j.intimp.2018.01.045
   PubMed Web of Science ®Google Scholar